Acquisition by Issa Mohamed Khairie of 48671 shares of Incyte subject to Rule 16b-3
| INCY Stock | USD 72.59 0.06 0.08% |
Slightly above 54% of Incyte's investor base is interested to short. The analysis of the overall investor sentiment regarding Incyte suggests that many traders are impartial. Incyte's investing sentiment can be driven by a variety of factors including economic data, Incyte's earnings reports, geopolitical events, and overall market trends.
Incyte |
Filed transaction by Incyte Officer: Evp, Head Of Us Oncology. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at finance.yahoo.com
 |
Incyte Fundamental Analysis
We analyze Incyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Incyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Incyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Incyte is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Incyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Incyte stock to make a market-neutral strategy. Peer analysis of Incyte could also be used in its relative valuation, which is a method of valuing Incyte by comparing valuation metrics with similar companies.
Peers
Incyte Related Equities
| IONS | Ionis Pharmaceuticals | 6.03 | ||||
| ALNY | Alnylam Pharmaceuticals | 1.17 | ||||
| DNLI | Denali Therapeutics | 0.13 | ||||
| UTHR | United Therapeutics | 0.29 | ||||
| FOLD | Amicus Therapeutics | 0.41 | ||||
| ARGX | Argenx NV | 0.50 | ||||
| BMRN | Biomarin Pharmaceutical | 0.74 | ||||
| AXSM | Axsome Therapeutics | 0.75 | ||||
| HRMY | Harmony Biosciences | 1.68 | ||||
| RARE | Ultragenyx | 1.78 | ||||
| ACAD | ACADIA Pharmaceuticals | 2.15 | ||||
| SRPT | Sarepta Therapeutics | 2.25 | ||||
| APLS | Apellis Pharmaceuticals | 2.47 | ||||
| ARWR | Arrowhead Pharmaceuticals | 3.58 |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.